schliessen

Filtern

 

Bibliotheken

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

Summary Background Dalcetrapib modulates cholesteryl ester transfer protein (CETP) activity to raise high-density lipoprotein cholesterol (HDL-C). After the failure of torcetrapib it was unknown if HDL produced by interaction with CETP had pro-atherogenic or pro-inflammatory properties. dal-PLAQUE i... Full description

Journal Title: The Lancet (British edition) 2011, Vol.378 (9802), p.1547-1559
Main Author: Fayad, Zahi A, Prof
Other Authors: Mani, Venkatesh, PhD , Woodward, Mark, Prof , Kallend, David, MB BS , Abt, Markus, PhD , Burgess, Tracy, MSc , Fuster, Valentin, Prof , Ballantyne, Christie M, Prof , Stein, Evan A, Prof , Tardif, Jean-Claude, Prof , Rudd, James H F, MD , Farkouh, Michael E, MD , Tawakol, Ahmed, MD
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: Kidlington: Elsevier Ltd
ID: ISSN: 0140-6736
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4151875
title: Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
format: Article
creator:
  • Fayad, Zahi A, Prof
  • Mani, Venkatesh, PhD
  • Woodward, Mark, Prof
  • Kallend, David, MB BS
  • Abt, Markus, PhD
  • Burgess, Tracy, MSc
  • Fuster, Valentin, Prof
  • Ballantyne, Christie M, Prof
  • Stein, Evan A, Prof
  • Tardif, Jean-Claude, Prof
  • Rudd, James H F, MD
  • Farkouh, Michael E, MD
  • Tawakol, Ahmed, MD
subjects:
  • Adolescent
  • Adult
  • Aged
  • Anticholesteremic Agents
  • Anticholesteremic Agents - administration & dosage
  • Article
  • Atherosclerosis
  • Atherosclerosis (general aspects, experimental research)
  • Biological and medical sciences
  • Blind Method
  • Blood and lymphatic vessels
  • carbohydrates (lipids)
  • Cardiology. Vascular system
  • Confidence Intervals
  • Coronary Artery Disease
  • Coronary Artery Disease - diagnosis
  • Coronary Artery Disease - prevention & control
  • Coronary Stenosis
  • Coronary Stenosis - diagnosis
  • Coronary Stenosis - prevention & control
  • Diagnosis
  • Diagnostic Imaging
  • Diagnostic Imaging - methods
  • Dose
  • Dose-Response Relationship, Drug
  • Double
  • Double-Blind Method
  • Drug
  • Drug Administration Schedule
  • Drug therapy
  • Drug Toxicity
  • Drug-Related Side Effects and Adverse Reactions
  • Emission Tomography
  • Female
  • Follow
  • Follow-Up Studies
  • General aspects
  • Health aspects
  • Humans
  • Hypercholesterolemia
  • Hypercholesterolemia - diagnosis
  • Hypercholesterolemia - drug therapy
  • Internal Medicine
  • lipids (amino acids
  • Magnetic Resonance Imaging
  • Magnetic Resonance Imaging - methods
  • Male
  • Medical sciences
  • Middle Aged
  • peptides
  • Positron
  • Positron-Emission Tomography - methods
  • proteins
  • Reference Values
  • Research
  • Response Relationship
  • Risk Assessment
  • Sulfhydryl Compounds
  • Sulfhydryl Compounds - administration & dosage
  • Treatment Outcome
  • Up Studies
  • Young Adult
ispartof: The Lancet (British edition), 2011, Vol.378 (9802), p.1547-1559
description: Summary Background Dalcetrapib modulates cholesteryl ester transfer protein (CETP) activity to raise high-density lipoprotein cholesterol (HDL-C). After the failure of torcetrapib it was unknown if HDL produced by interaction with CETP had pro-atherogenic or pro-inflammatory properties. dal-PLAQUE is the first multicentre study using novel non-invasive multimodality imaging to assess structural and inflammatory indices of atherosclerosis as primary endpoints. Methods In this phase 2b, double-blind, multicentre trial, patients (aged 18–75 years) with, or with high risk of, coronary heart disease were randomly assigned (1:1) to dalcetrapib 600 mg/day or placebo for 24 months. Randomisation was done with a computer-generated randomisation code and was stratified by centre. Patients and investigators were masked to treatment. Coprimary endpoints were MRI-assessed indices (total vessel area, wall area, wall thickness, and normalised wall index [average carotid]) after 24 months and18 F-fluorodeoxyglucose (18 F-FDG) PET/CT assessment of arterial inflammation within an index vessel (right carotid, left carotid, or ascending thoracic aorta) after 6 months, with no-harm boundaries established before unblinding of the trial. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov , NCT00655473. Findings 189 patients were screened and 130 randomly assigned to placebo (66 patients) or dalcetrapib (64 patients). For the coprimary MRI and PET/CT endpoints, CIs were below the no-harm boundary or the adverse change was numerically lower in the dalcetrapib group than in the placebo group. MRI-derived change in total vessel area was reduced in patients given dalcetrapib compared with those given placebo after 24 months; absolute change from baseline relative to placebo was −4·01 mm2 (90% CI −7·23 to −0·80; nominal p=0·04). The PET/CT measure of index vessel most-diseased-segment target-to-background ratio (TBR) was not different between groups, but carotid artery analysis showed a 7% reduction in most-diseased-segment TBR in the dalcetrapib group compared with the placebo group (–7·3 [90% CI −13·5 to −0·8]; nominal p=0·07). Dalcetrapib did not increase office blood pressure and the frequency of adverse events was similar between groups. Interpretation Dalcetrapib showed no evidence of a pathological effect related to the arterial wall over 24 months. Moreover, this trial suggests possible beneficial vascular effects of dalcetrapib, including the r
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.7597394
LOCALfalse
PrimoNMBib
record
control
sourceidgale_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4151875
sourceformatXML
sourcesystemPC
galeidA271141517
sourcerecordidA271141517
originalsourceidFETCH-LOGICAL-1756t-8752fab5772568c4012d2126457f91f7f1eec6e02e28692d04819ad736ea96a3
addsrcrecordideNqFkt1u1DAQhSMEoqXwCKDcgFqJFE9iOwlIRVVVfqSKH7VI3Flee7zrNmuv4uyifRGel0m3LW1veuMoyZlvZnxOlr0Etg8M5LtTBpwVsq7kLsCehKqpCv4o2wZe80Lw-vfjbPtGspU9S-mcMcYlE0-zrRJa1rBKbmd_T7XDYZ3rYHN0zhtt1nl0udWdwaHXCz_JY8j1MMM-JtPROXiTW59QJ8yXyYdpHuIKOzpD4cNKJ7_CfL7sBj-PhPFE93M9HYW79F78ODn8-et4732u857axjmxbG46H6h7lw-9193z7InTXcIXV8-d7OzT8dnRl-Lk--evR4cnBdRCDkVTi9LpiajrUsjGcAalLaGUXNSuBVc7QDQSWYllI9vSMt5Aqy3dCOpW6monO9hgF8vJHK3BQCt3atHTwP1aRe3V3T_Bz9Q0rhQHAdScAN82gLjAoH2Pd2ptwEFZtMuF-uMUY6DKemJcI2RrHUrQohZklTDQToxmlagIuL8BTnWHygcXqS-Zoi3OvYkBnafvh2UNMM5QU8GbWwUz1N0wS7FbDj6GdFf49pZwMjqHiY7kp7MhTfUy3ZOLjdyQ76lHd7MZMDUmUF0mUI3xUgDqMoGKU92r21d6U3UdORK8vhLoRH47yoDx6b-Oy7YBPuo-3BvA-EGPa9GN-O7BMT5uqpHSs_LYq2Q8BoOWTDLkSvQPEg7uEa4jeoFrTOdx2QeKpgKVSsU2kJEBcEng1T9LCB_0
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
display
typearticle
titleSafety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
sourceAlma/SFX Local Collection
creatorFayad, Zahi A, Prof ; Mani, Venkatesh, PhD ; Woodward, Mark, Prof ; Kallend, David, MB BS ; Abt, Markus, PhD ; Burgess, Tracy, MSc ; Fuster, Valentin, Prof ; Ballantyne, Christie M, Prof ; Stein, Evan A, Prof ; Tardif, Jean-Claude, Prof ; Rudd, James H F, MD ; Farkouh, Michael E, MD ; Tawakol, Ahmed, MD
creatorcontribFayad, Zahi A, Prof ; Mani, Venkatesh, PhD ; Woodward, Mark, Prof ; Kallend, David, MB BS ; Abt, Markus, PhD ; Burgess, Tracy, MSc ; Fuster, Valentin, Prof ; Ballantyne, Christie M, Prof ; Stein, Evan A, Prof ; Tardif, Jean-Claude, Prof ; Rudd, James H F, MD ; Farkouh, Michael E, MD ; Tawakol, Ahmed, MD ; for the dal-PLAQUE Investigators ; dal-PLAQUE Investigators
descriptionSummary Background Dalcetrapib modulates cholesteryl ester transfer protein (CETP) activity to raise high-density lipoprotein cholesterol (HDL-C). After the failure of torcetrapib it was unknown if HDL produced by interaction with CETP had pro-atherogenic or pro-inflammatory properties. dal-PLAQUE is the first multicentre study using novel non-invasive multimodality imaging to assess structural and inflammatory indices of atherosclerosis as primary endpoints. Methods In this phase 2b, double-blind, multicentre trial, patients (aged 18–75 years) with, or with high risk of, coronary heart disease were randomly assigned (1:1) to dalcetrapib 600 mg/day or placebo for 24 months. Randomisation was done with a computer-generated randomisation code and was stratified by centre. Patients and investigators were masked to treatment. Coprimary endpoints were MRI-assessed indices (total vessel area, wall area, wall thickness, and normalised wall index [average carotid]) after 24 months and18 F-fluorodeoxyglucose (18 F-FDG) PET/CT assessment of arterial inflammation within an index vessel (right carotid, left carotid, or ascending thoracic aorta) after 6 months, with no-harm boundaries established before unblinding of the trial. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov , NCT00655473. Findings 189 patients were screened and 130 randomly assigned to placebo (66 patients) or dalcetrapib (64 patients). For the coprimary MRI and PET/CT endpoints, CIs were below the no-harm boundary or the adverse change was numerically lower in the dalcetrapib group than in the placebo group. MRI-derived change in total vessel area was reduced in patients given dalcetrapib compared with those given placebo after 24 months; absolute change from baseline relative to placebo was −4·01 mm2 (90% CI −7·23 to −0·80; nominal p=0·04). The PET/CT measure of index vessel most-diseased-segment target-to-background ratio (TBR) was not different between groups, but carotid artery analysis showed a 7% reduction in most-diseased-segment TBR in the dalcetrapib group compared with the placebo group (–7·3 [90% CI −13·5 to −0·8]; nominal p=0·07). Dalcetrapib did not increase office blood pressure and the frequency of adverse events was similar between groups. Interpretation Dalcetrapib showed no evidence of a pathological effect related to the arterial wall over 24 months. Moreover, this trial suggests possible beneficial vascular effects of dalcetrapib, including the reduction in total vessel enlargement over 24 months, but long-term safety and clinical outcomes efficacy of dalcetrapib need to be analysed. Funding F Hoffmann-La Roche Ltd.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(11)61383-4
3PMID: 21908036
4CODEN: LANCAO
languageeng
publisherKidlington: Elsevier Ltd
subjectAdolescent ; Adult ; Aged ; Anticholesteremic Agents ; Anticholesteremic Agents - administration & dosage ; Article ; Atherosclerosis ; Atherosclerosis (general aspects, experimental research) ; Biological and medical sciences ; Blind Method ; Blood and lymphatic vessels ; carbohydrates (lipids) ; Cardiology. Vascular system ; Confidence Intervals ; Coronary Artery Disease ; Coronary Artery Disease - diagnosis ; Coronary Artery Disease - prevention & control ; Coronary Stenosis ; Coronary Stenosis - diagnosis ; Coronary Stenosis - prevention & control ; Diagnosis ; Diagnostic Imaging ; Diagnostic Imaging - methods ; Dose ; Dose-Response Relationship, Drug ; Double ; Double-Blind Method ; Drug ; Drug Administration Schedule ; Drug therapy ; Drug Toxicity ; Drug-Related Side Effects and Adverse Reactions ; Emission Tomography ; Female ; Follow ; Follow-Up Studies ; General aspects ; Health aspects ; Humans ; Hypercholesterolemia ; Hypercholesterolemia - diagnosis ; Hypercholesterolemia - drug therapy ; Internal Medicine ; lipids (amino acids ; Magnetic Resonance Imaging ; Magnetic Resonance Imaging - methods ; Male ; Medical sciences ; Middle Aged ; peptides ; Positron ; Positron-Emission Tomography - methods ; proteins ; Reference Values ; Research ; Response Relationship ; Risk Assessment ; Sulfhydryl Compounds ; Sulfhydryl Compounds - administration & dosage ; Treatment Outcome ; Up Studies ; Young Adult
ispartofThe Lancet (British edition), 2011, Vol.378 (9802), p.1547-1559
rights
0Elsevier Ltd
12011 Elsevier Ltd
22015 INIST-CNRS
3Copyright © 2011 Elsevier Ltd. All rights reserved.
4COPYRIGHT 2011 Elsevier B.V.
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1756t-8752fab5772568c4012d2126457f91f7f1eec6e02e28692d04819ad736ea96a3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24698146$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21908036$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Fayad, Zahi A, Prof
1Mani, Venkatesh, PhD
2Woodward, Mark, Prof
3Kallend, David, MB BS
4Abt, Markus, PhD
5Burgess, Tracy, MSc
6Fuster, Valentin, Prof
7Ballantyne, Christie M, Prof
8Stein, Evan A, Prof
9Tardif, Jean-Claude, Prof
10Rudd, James H F, MD
11Farkouh, Michael E, MD
12Tawakol, Ahmed, MD
13for the dal-PLAQUE Investigators
14dal-PLAQUE Investigators
title
0Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
1The Lancet (British edition)
addtitleLancet
descriptionSummary Background Dalcetrapib modulates cholesteryl ester transfer protein (CETP) activity to raise high-density lipoprotein cholesterol (HDL-C). After the failure of torcetrapib it was unknown if HDL produced by interaction with CETP had pro-atherogenic or pro-inflammatory properties. dal-PLAQUE is the first multicentre study using novel non-invasive multimodality imaging to assess structural and inflammatory indices of atherosclerosis as primary endpoints. Methods In this phase 2b, double-blind, multicentre trial, patients (aged 18–75 years) with, or with high risk of, coronary heart disease were randomly assigned (1:1) to dalcetrapib 600 mg/day or placebo for 24 months. Randomisation was done with a computer-generated randomisation code and was stratified by centre. Patients and investigators were masked to treatment. Coprimary endpoints were MRI-assessed indices (total vessel area, wall area, wall thickness, and normalised wall index [average carotid]) after 24 months and18 F-fluorodeoxyglucose (18 F-FDG) PET/CT assessment of arterial inflammation within an index vessel (right carotid, left carotid, or ascending thoracic aorta) after 6 months, with no-harm boundaries established before unblinding of the trial. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov , NCT00655473. Findings 189 patients were screened and 130 randomly assigned to placebo (66 patients) or dalcetrapib (64 patients). For the coprimary MRI and PET/CT endpoints, CIs were below the no-harm boundary or the adverse change was numerically lower in the dalcetrapib group than in the placebo group. MRI-derived change in total vessel area was reduced in patients given dalcetrapib compared with those given placebo after 24 months; absolute change from baseline relative to placebo was −4·01 mm2 (90% CI −7·23 to −0·80; nominal p=0·04). The PET/CT measure of index vessel most-diseased-segment target-to-background ratio (TBR) was not different between groups, but carotid artery analysis showed a 7% reduction in most-diseased-segment TBR in the dalcetrapib group compared with the placebo group (–7·3 [90% CI −13·5 to −0·8]; nominal p=0·07). Dalcetrapib did not increase office blood pressure and the frequency of adverse events was similar between groups. Interpretation Dalcetrapib showed no evidence of a pathological effect related to the arterial wall over 24 months. Moreover, this trial suggests possible beneficial vascular effects of dalcetrapib, including the reduction in total vessel enlargement over 24 months, but long-term safety and clinical outcomes efficacy of dalcetrapib need to be analysed. Funding F Hoffmann-La Roche Ltd.
subject
0Adolescent
1Adult
2Aged
3Anticholesteremic Agents
4Anticholesteremic Agents - administration & dosage
5Article
6Atherosclerosis
7Atherosclerosis (general aspects, experimental research)
8Biological and medical sciences
9Blind Method
10Blood and lymphatic vessels
11carbohydrates (lipids)
12Cardiology. Vascular system
13Confidence Intervals
14Coronary Artery Disease
15Coronary Artery Disease - diagnosis
16Coronary Artery Disease - prevention & control
17Coronary Stenosis
18Coronary Stenosis - diagnosis
19Coronary Stenosis - prevention & control
20Diagnosis
21Diagnostic Imaging
22Diagnostic Imaging - methods
23Dose
24Dose-Response Relationship, Drug
25Double
26Double-Blind Method
27Drug
28Drug Administration Schedule
29Drug therapy
30Drug Toxicity
31Drug-Related Side Effects and Adverse Reactions
32Emission Tomography
33Female
34Follow
35Follow-Up Studies
36General aspects
37Health aspects
38Humans
39Hypercholesterolemia
40Hypercholesterolemia - diagnosis
41Hypercholesterolemia - drug therapy
42Internal Medicine
43lipids (amino acids
44Magnetic Resonance Imaging
45Magnetic Resonance Imaging - methods
46Male
47Medical sciences
48Middle Aged
49peptides
50Positron
51Positron-Emission Tomography - methods
52proteins
53Reference Values
54Research
55Response Relationship
56Risk Assessment
57Sulfhydryl Compounds
58Sulfhydryl Compounds - administration & dosage
59Treatment Outcome
60Up Studies
61Young Adult
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2011
recordtypearticle
recordideNqFkt1u1DAQhSMEoqXwCKDcgFqJFE9iOwlIRVVVfqSKH7VI3Flee7zrNmuv4uyifRGel0m3LW1veuMoyZlvZnxOlr0Etg8M5LtTBpwVsq7kLsCehKqpCv4o2wZe80Lw-vfjbPtGspU9S-mcMcYlE0-zrRJa1rBKbmd_T7XDYZ3rYHN0zhtt1nl0udWdwaHXCz_JY8j1MMM-JtPROXiTW59QJ8yXyYdpHuIKOzpD4cNKJ7_CfL7sBj-PhPFE93M9HYW79F78ODn8-et4732u857axjmxbG46H6h7lw-9193z7InTXcIXV8-d7OzT8dnRl-Lk--evR4cnBdRCDkVTi9LpiajrUsjGcAalLaGUXNSuBVc7QDQSWYllI9vSMt5Aqy3dCOpW6monO9hgF8vJHK3BQCt3atHTwP1aRe3V3T_Bz9Q0rhQHAdScAN82gLjAoH2Pd2ptwEFZtMuF-uMUY6DKemJcI2RrHUrQohZklTDQToxmlagIuL8BTnWHygcXqS-Zoi3OvYkBnafvh2UNMM5QU8GbWwUz1N0wS7FbDj6GdFf49pZwMjqHiY7kp7MhTfUy3ZOLjdyQ76lHd7MZMDUmUF0mUI3xUgDqMoGKU92r21d6U3UdORK8vhLoRH47yoDx6b-Oy7YBPuo-3BvA-EGPa9GN-O7BMT5uqpHSs_LYq2Q8BoOWTDLkSvQPEg7uEa4jeoFrTOdx2QeKpgKVSsU2kJEBcEng1T9LCB_0
startdate2011
enddate2011
creator
0Fayad, Zahi A, Prof
1Mani, Venkatesh, PhD
2Woodward, Mark, Prof
3Kallend, David, MB BS
4Abt, Markus, PhD
5Burgess, Tracy, MSc
6Fuster, Valentin, Prof
7Ballantyne, Christie M, Prof
8Stein, Evan A, Prof
9Tardif, Jean-Claude, Prof
10Rudd, James H F, MD
11Farkouh, Michael E, MD
12Tawakol, Ahmed, MD
general
0Elsevier Ltd
1Elsevier
2Elsevier B.V
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
10BOBZL
11CLFQK
125PM
sort
creationdate2011
titleSafety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
authorFayad, Zahi A, Prof ; Mani, Venkatesh, PhD ; Woodward, Mark, Prof ; Kallend, David, MB BS ; Abt, Markus, PhD ; Burgess, Tracy, MSc ; Fuster, Valentin, Prof ; Ballantyne, Christie M, Prof ; Stein, Evan A, Prof ; Tardif, Jean-Claude, Prof ; Rudd, James H F, MD ; Farkouh, Michael E, MD ; Tawakol, Ahmed, MD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1756t-8752fab5772568c4012d2126457f91f7f1eec6e02e28692d04819ad736ea96a3
rsrctypearticles
prefilterarticles
languageeng
creationdate2011
topic
0Adolescent
1Adult
2Aged
3Anticholesteremic Agents
4Anticholesteremic Agents - administration & dosage
5Article
6Atherosclerosis
7Atherosclerosis (general aspects, experimental research)
8Biological and medical sciences
9Blind Method
10Blood and lymphatic vessels
11carbohydrates (lipids)
12Cardiology. Vascular system
13Confidence Intervals
14Coronary Artery Disease
15Coronary Artery Disease - diagnosis
16Coronary Artery Disease - prevention & control
17Coronary Stenosis
18Coronary Stenosis - diagnosis
19Coronary Stenosis - prevention & control
20Diagnosis
21Diagnostic Imaging
22Diagnostic Imaging - methods
23Dose
24Dose-Response Relationship, Drug
25Double
26Double-Blind Method
27Drug
28Drug Administration Schedule
29Drug therapy
30Drug Toxicity
31Drug-Related Side Effects and Adverse Reactions
32Emission Tomography
33Female
34Follow
35Follow-Up Studies
36General aspects
37Health aspects
38Humans
39Hypercholesterolemia
40Hypercholesterolemia - diagnosis
41Hypercholesterolemia - drug therapy
42Internal Medicine
43lipids (amino acids
44Magnetic Resonance Imaging
45Magnetic Resonance Imaging - methods
46Male
47Medical sciences
48Middle Aged
49peptides
50Positron
51Positron-Emission Tomography - methods
52proteins
53Reference Values
54Research
55Response Relationship
56Risk Assessment
57Sulfhydryl Compounds
58Sulfhydryl Compounds - administration & dosage
59Treatment Outcome
60Up Studies
61Young Adult
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Fayad, Zahi A, Prof
1Mani, Venkatesh, PhD
2Woodward, Mark, Prof
3Kallend, David, MB BS
4Abt, Markus, PhD
5Burgess, Tracy, MSc
6Fuster, Valentin, Prof
7Ballantyne, Christie M, Prof
8Stein, Evan A, Prof
9Tardif, Jean-Claude, Prof
10Rudd, James H F, MD
11Farkouh, Michael E, MD
12Tawakol, Ahmed, MD
13for the dal-PLAQUE Investigators
14dal-PLAQUE Investigators
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9OpenAIRE (Open Access)
10OpenAIRE
11PubMed Central (Full Participant titles)
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Fayad, Zahi A, Prof
1Mani, Venkatesh, PhD
2Woodward, Mark, Prof
3Kallend, David, MB BS
4Abt, Markus, PhD
5Burgess, Tracy, MSc
6Fuster, Valentin, Prof
7Ballantyne, Christie M, Prof
8Stein, Evan A, Prof
9Tardif, Jean-Claude, Prof
10Rudd, James H F, MD
11Farkouh, Michael E, MD
12Tawakol, Ahmed, MD
aucorp
0for the dal-PLAQUE Investigators
1dal-PLAQUE Investigators
formatjournal
genrearticle
ristypeJOUR
atitleSafety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
jtitleThe Lancet (British edition)
addtitleLancet
date2011
risdate2011
volume378
issue9802
spage1547
epage1559
pages1547-1559
issn0140-6736
eissn1474-547X
codenLANCAO
abstractSummary Background Dalcetrapib modulates cholesteryl ester transfer protein (CETP) activity to raise high-density lipoprotein cholesterol (HDL-C). After the failure of torcetrapib it was unknown if HDL produced by interaction with CETP had pro-atherogenic or pro-inflammatory properties. dal-PLAQUE is the first multicentre study using novel non-invasive multimodality imaging to assess structural and inflammatory indices of atherosclerosis as primary endpoints. Methods In this phase 2b, double-blind, multicentre trial, patients (aged 18–75 years) with, or with high risk of, coronary heart disease were randomly assigned (1:1) to dalcetrapib 600 mg/day or placebo for 24 months. Randomisation was done with a computer-generated randomisation code and was stratified by centre. Patients and investigators were masked to treatment. Coprimary endpoints were MRI-assessed indices (total vessel area, wall area, wall thickness, and normalised wall index [average carotid]) after 24 months and18 F-fluorodeoxyglucose (18 F-FDG) PET/CT assessment of arterial inflammation within an index vessel (right carotid, left carotid, or ascending thoracic aorta) after 6 months, with no-harm boundaries established before unblinding of the trial. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov , NCT00655473. Findings 189 patients were screened and 130 randomly assigned to placebo (66 patients) or dalcetrapib (64 patients). For the coprimary MRI and PET/CT endpoints, CIs were below the no-harm boundary or the adverse change was numerically lower in the dalcetrapib group than in the placebo group. MRI-derived change in total vessel area was reduced in patients given dalcetrapib compared with those given placebo after 24 months; absolute change from baseline relative to placebo was −4·01 mm2 (90% CI −7·23 to −0·80; nominal p=0·04). The PET/CT measure of index vessel most-diseased-segment target-to-background ratio (TBR) was not different between groups, but carotid artery analysis showed a 7% reduction in most-diseased-segment TBR in the dalcetrapib group compared with the placebo group (–7·3 [90% CI −13·5 to −0·8]; nominal p=0·07). Dalcetrapib did not increase office blood pressure and the frequency of adverse events was similar between groups. Interpretation Dalcetrapib showed no evidence of a pathological effect related to the arterial wall over 24 months. Moreover, this trial suggests possible beneficial vascular effects of dalcetrapib, including the reduction in total vessel enlargement over 24 months, but long-term safety and clinical outcomes efficacy of dalcetrapib need to be analysed. Funding F Hoffmann-La Roche Ltd.
copKidlington
pubElsevier Ltd
pmid21908036
doi10.1016/S0140-6736(11)61383-4
oafree_for_read